Wechselwirkungen · Adcirca (previously Tadalafil Lilly)
ADCIRCA 2 mg/mL oral suspension · Abschnitt 4.5 · PDF-Seite 24
HOS-210140 · Präparat HOS-154449
Riociguat Preclinical trials showed an additive systemic blood pressure lowering effect when PDE5 inhibitors were combined with riociguat. In clinical trials, riociguat has been shown to augment the hypotensive effects of PDE5 inhibitors. There was no evidence of favourable clinical effect of the combination in the population studied. Concomitant use of riociguat with PDE5 inhibitors, including tadalafil, is contraindicated (see section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): riociguat (HOS-086293)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-27T15:17:00Z · SHA-256 f45503711a580d9fd5973be63b2c67b7830a1e53d77892c603581b2f6ee084ab · Passage d0752ac444727da2789bc840d1f1de79c1787247d102c24a4a84c0b48998643b · Zeichen 3463–3909 im Abschnitt